Biostatistician Abisola Idu, MS, MPH, is interested in research that investigates the effectiveness and efficacy of treatment in pharmacoepidemiologic studies. She has a broad range of interest in research with a strong motivation to investigate the health challenges of malaria, obesity, cancer, heart disease, and maternal health.
Ms. Idu began her contributions to clinical and public health research through her academic training at the University of Texas Health Science Center, School of Public Health. She further got rigorous research experience by being a part of the leukemia, lymphoma, and cancer prevention research team at The University of Texas M.D. Anderson Cancer Center in 2015. She has been a biostatistician at Kaiser Permanente Washington Health Research Institute's Biostatistics Unit since 2018.
Ms. Idu looks forward to using her expertise in application of epidemiological principles and surveillance methodologies at KPWHRI. She has an in-depth knowledge of the ICH-GCP, FDA, IRB policies, regulations, and guidelines and plans to use her skills and background to implement epidemiologic study designs in clinical research studies.
Efficacy and safety of therapies; association between genetic variability and survival outcomes
Role of nutritional, psychological and lifestyle factors; obesity prevention and control
Role of aging, nutritional and lifestyle factors; Intervention strategies for prevention and disease control
Association between social, behavioral and clinical factors and maternal and infant outcomes
Malaria prevention and control; development of vaccines; availability and accessibility to malaria treatment
Bradley KA, Hyun N, Idu A, Yu O, Bobb JF, Wartko PD, Weinstein Z, Matthews AG, McCormack J, Lee AK, Samet JH Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial 2026 Mar;121(3):629-642 doi:10.1111/add.70221. doi: 10.1111/add.70221. Epub 2025-11-24. PubMed
Hyun N, Idu AE, Cook AJ, Bobb JF Increased risk of type I errors for detecting heterogeneity of treatment effects in cluster-randomized trials using mixed-effect models 2026 Jan 12 doi: 10.1186/s12874-025-02744-6. Epub 2026-01-12. PubMed
Wong ES, Dorsey CN, Beatty TC, Bobb JF, Stefanik-Guizlo K, Key DL, Ramaprasan A, Idu AE, Fortney JC, Mogk J, Palazzo L, Caldeiro RM, King D, McWethy AG, Glass JE Economic cost of strategic implementation approaches to increase uptake of digital therapeutics for substance use disorders in a large integrated health system 2026 Jan;5(1):e0001145. doi: 10.1371/journal.pdig.0001145. Epub 2026-01-08. PubMed
Matson TE, Navarro MA, Idu A, Bobb JF, Patrick BM, Phillips R, Barrett TD, Rossi FS, Krawczyk N, Doud R, Rogers K, Davis CJ, Caldeiro R, Glass JE Design of a cluster-randomized, hybrid type 1 effectiveness-implementation trial of a care navigation intervention to increase substance use disorder treatment engagement: study protocol 2025 Oct;20(1):78. doi: 10.1186/s13722-025-00605-7. Epub 2025-10-01. PubMed
Greenwood-Hickman MA, Zhu W, Idu A, Harrington LB, McCurry SM, LaCroix AZ, Shaw PA, Rosenberg DE Associations Between 10-Year Physical Performance and Activities of Daily Living Trajectories and Physical Behaviors in Older Adults 2025 Apr 29;22(5). doi: 10.3390/ijerph22050704. Epub 2025-04-29. PubMed
Greenwood-Hickman MA, Walker RL, Idu AE, Bellettiere J, Wing D, McCurry SM, Crane PK, Larson EB, Rosenberg DE, LaCroix AZ Current and historic patterns of chronic disease burden are associated with physical activity and sedentary behavior in older adults: an observational study 2025 Mar 17;25(1):1032. doi: 10.1186/s12889-025-22264-8. Epub 2025-03-17. PubMed
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
In a new study, a tool to help discover undiagnosed dementia performed well in 2 separate health systems.
A study led by Dr. Sascha Dublin finds similar outcomes for 3 hypertension medications, filling an evidence gap.
New work by Susan Shortreed, PhD, finds infection risks drive worse outcomes for some racial and ethnic groups.